- The FDA, in a notice Wednesday, said bebtelovimab is no longer authorized for use because it is not expected to neutralize the omicron BQ.1 and BQ.1.1 subvariants.
- U.S. health officials have warned that people with weak immune systems face a heightened risk from Covid this winter, because omicron subvariants threaten to knock out antibody treatments.
- President Joe Biden has called on people with weak immune systems to consult with their physicians about what extra precautions they should take this winter to stay safe.
Disclaimer: This story is generated from RSS Feed and has not been created or edited by Waba News. Publisher: CNBC